The impact of this deal on the stock market has been quite bullish, especially for AI-related companies and those involved in ...

The stock has spent the past few years in the shadow of a COVID-19 boost, but it's time investors see the light.

Shares of Moderna closed nearly 17% lower Monday. Other vaccine stocks also fell, with Novavax and BioNTech both ending more than 7% lower. "As we head into 2025, there are a handful of uncertainties ...

H.C. Wainwright analyst Edward White reiterated a Buy rating on Valneva (VALN – Research Report) today and set a price target of $18.00.Invest ...

Shares of vaccine makers including Moderna, Novavax and CureVac rose Tuesday after U.S. health officials confirmed the first American death caused by the H5N1 bird flu. Moderna and Novavax shares ...

Moderna (NASDAQ: MRNA) was one of the hottest companies of early pandemic times, delivering a coronavirus vaccine to market ...

Moderna surged as investors turned eyed potential demand for a vaccine to protect against bird flu after the US reported its first death from the virus.

The Louisiana Department of Health noted yesterday that a 65-year-old hospital patient had died due to bird flu.

David Risinger, an analyst from Leerink Partners, reiterated the Buy rating on Vaxcyte (PCVX – Research Report). The associated price target ...